{"id":253114,"date":"2024-12-07T14:53:28","date_gmt":"2024-12-07T13:53:28","guid":{"rendered":"https:\/\/r3i.org\/seminarios-web\/"},"modified":"2026-06-23T15:03:05","modified_gmt":"2026-06-23T13:03:05","slug":"seminarios-web","status":"publish","type":"page","link":"https:\/\/r3i.org\/es\/seminarios-web\/","title":{"rendered":"Seminarios web"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ admin_label=\u00bbHeader\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bb35f37621-1062-4ae6-955d-76a3167a2aa8″ background_image=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/webinar-5220471_1280.jpg\u00bb parallax=\u00bbon\u00bb min_height=\u00bb158px\u00bb min_height_tablet=\u00bb158px\u00bb min_height_phone=\u00bb634px\u00bb min_height_last_edited=\u00bbon|phone\u00bb height=\u00bb450px\u00bb height_tablet=\u00bb400px\u00bb height_phone=\u00bb626px\u00bb height_last_edited=\u00bbon|phone\u00bb custom_padding=\u00bb6vw||6vw||true|false\u00bb collapsed=\u00bbon\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22background_color_gradient_stops%22%93}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-69px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbWEBINARIOS\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbbe7faa8d-05f5-42a0-9582-c8e8739f13b6″ title_font=\u00bbPoppins||||||||\u00bb title_text_align=\u00bbleft\u00bb title_text_color=\u00bb#FFFFFF\u00bb title_font_size=\u00bb47px\u00bb custom_margin_tablet=\u00bb\u00bb custom_margin_phone=\u00bb60px|0px|-100px||false|false\u00bb custom_margin_last_edited=\u00bbon|phone\u00bb custom_padding=\u00bb12px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb custom_margin=\u00bb-30px||||false|false\u00bb custom_margin_tablet=\u00bb-30px||||false|false\u00bb custom_margin_phone=\u00bb100px||||false|false\u00bb custom_margin_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n

\u00a1Bienvenido\/a a la secci\u00f3n de Webinars de la Fundaci\u00f3n R3i! Aqu\u00ed ofrecemos una plataforma para el intercambio de conocimientos y el debate sobre temas clave relacionados con la salud vascular y el riesgo residual. Nuestros webinars cuentan con la participaci\u00f3n de reconocidos expertos de todo el mundo, que comparten sus conocimientos, investigaciones y estrategias innovadoras orientadas a mejorar nuestra comprensi\u00f3n y el manejo de las afecciones vasculares. Al participar, tendr\u00e1 acceso a informaci\u00f3n valiosa, conocer\u00e1 los \u00faltimos avances en investigaci\u00f3n y podr\u00e1 interactuar con l\u00edderes de opini\u00f3n en el campo. Explore nuestros pr\u00f3ximos webinars y acceda a las grabaciones de sesiones anteriores para mantenerse informado\/a y comprometido\/a. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.27.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.3″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-49px|||||\u00bb custom_padding=\u00bb2px||54px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_3_text_color=\u00bbgcid-primary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22header_3_text_color%22%93}\u00bb]<\/p>\n

2026 <\/span><\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][divi_videopress _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/divi_videopress][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2026\/06\/Record-Webinar-R3I-Spain.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb title_text=\u00bbRecord Webinar R3I Spain\u00bb sticky_enabled=\u00bb0″][\/et_pb_video][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.6em\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Mim\u00e9ticos de incretinas en la enfermedad cardiometab\u00f3lica: \u00bfhasta d\u00f3nde pueden llegar para abordar el riesgo residual?<\/h5>\n

2026<\/p>\n

Pr. Michel Hermans <\/h6>\n

Este webinar analiza los datos de los principales ensayos cl\u00ednicos de resultados cardiovasculares (CVOT) con agonistas del receptor del GLP-1 (GLP-1-RA) y agonistas duales, que han demostrado, en varios componentes de estas clases terap\u00e9uticas, una reducci\u00f3n no solo de los criterios de valoraci\u00f3n primarios, sino tambi\u00e9n de otras comorbilidades cardiorrenales y metab\u00f3licas. Tambi\u00e9n se analizan los beneficios observados en la reducci\u00f3n de la mortalidad cardiovascular y por todas las causas, con una clasificaci\u00f3n de los ensayos CVOT basada en la reducci\u00f3n relativa frente a la absoluta, as\u00ed como en t\u00e9rminos de reducci\u00f3n del riesgo residual de comorbilidades espec\u00edficas de \u00f3rganos, como ictus, enfermedad renal o insuficiencia card\u00edaca. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_3_text_color=\u00bbgcid-primary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22header_3_text_color%22%93}\u00bb]<\/p>\n

2024 <\/span><\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb border_radii=\u00bbon|18px|18px|18px|18px\u00bb border_width_all=\u00bb1px\u00bb border_color_all=\u00bbgcid-79008fab-ccde-4aaf-8238-1144e270bf33″ box_shadow_style=\u00bbpreset2″ global_colors_info=\u00bb{%22gcid-79008fab-ccde-4aaf-8238-1144e270bf33%22:%91%22border_color_all%22%93}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Webinar-june-2024_0.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.7em\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Pemafibrato para Tratar y Prevenir la Ulceraci\u00f3n del Pie Diab\u00e9tico: Una Necesidad Cl\u00ednica Insatisfecha que Requiere una Evaluaci\u00f3n Formal<\/span><\/h5>\n

2024<\/span><\/p>\n

Pr. Paul Ridker <\/span><\/h6>\n

Este v\u00eddeo profundiza en el tratamiento cr\u00edtico de las \u00falceras del pie diab\u00e9tico y en el papel potencial del pemafibrato para abordar este acuciante problema de salud. Con las opiniones de destacados expertos, analiza las limitaciones actuales del tratamiento y la urgente necesidad de realizar evaluaciones formales de la eficacia del pemafibrato. No pierdas la oportunidad de mejorar tu comprensi\u00f3n de este tema vital y de c\u00f3mo puede influir en la atenci\u00f3n futura de la diabetes. \u00a1M\u00edralo ahora! <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb20px||||false|false\u00bb border_radii=\u00bbon|18px|18px|18px|18px\u00bb border_width_all=\u00bb1px\u00bb border_color_all=\u00bbgcid-79008fab-ccde-4aaf-8238-1144e270bf33″ box_shadow_style=\u00bbpreset2″ global_colors_info=\u00bb{%22gcid-79008fab-ccde-4aaf-8238-1144e270bf33%22:%91%22border_color_all%22%93}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/Webinar-fevrier-2024-remixed.mp4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.7em\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Avances recientes en la farmacoterapia de la retinopat\u00eda diab\u00e9tica en la diabetes mellitus tipo 2: Agonistas PPAR\u0251<\/span><\/h5>\n

2024<\/span><\/p>\n

Pr. Alberto Zambon <\/span><\/h6>\n

Esta presentaci\u00f3n en v\u00eddeo se centra en el importante papel de los agonistas PPAR\u0251 en el tratamiento de la retinopat\u00eda diab\u00e9tica, explorando sus mecanismos de acci\u00f3n, eficacia cl\u00ednica y beneficios potenciales para los pacientes. Descubre los \u00faltimos descubrimientos y perspectivas que pueden ayudar a redefinir el panorama terap\u00e9utico de la retinopat\u00eda diab\u00e9tica. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb header_3_text_color=\u00bbgcid-primary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22header_3_text_color%22%93}\u00bb]<\/p>\n

M\u00e1s webinarios <\/span><\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb20px||||false|false\u00bb border_radii=\u00bbon|18px|18px|18px|18px\u00bb border_width_all=\u00bb1px\u00bb border_color_all=\u00bbgcid-79008fab-ccde-4aaf-8238-1144e270bf33″ box_shadow_style=\u00bbpreset2″ global_colors_info=\u00bb{%22gcid-79008fab-ccde-4aaf-8238-1144e270bf33%22:%91%22border_color_all%22%93}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/webinar_ACCORD.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.7em\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Webinar sobre el estudio ACCORD<\/span><\/h5>\n

2014<\/span><\/p>\n

Pr. Michel Hermans <\/span><\/h6>\n

El ensayo ACCORD, o Acci\u00f3n para controlar los riesgos en pacientes con diabetes tipo 2. Su objetivo era comparar los efectos de distintas estrategias para reducir los niveles de az\u00facar en sangre y su repercusi\u00f3n en los resultados cardiovasculares. El ensayo incluy\u00f3 m\u00faltiples intervenciones, como el control intensivo de la glucosa, el control de la presi\u00f3n arterial y la reducci\u00f3n del colesterol. Las principales conclusiones indicaron que, aunque el control intensivo de la glucosa mejor\u00f3 los niveles de hemoglobina A1c, no redujo significativamente el riesgo de acontecimientos cardiovasculares graves. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb20px||||false|false\u00bb border_radii=\u00bbon|18px|18px|18px|18px\u00bb border_width_all=\u00bb1px\u00bb border_color_all=\u00bbgcid-79008fab-ccde-4aaf-8238-1144e270bf33″ box_shadow_style=\u00bbpreset2″ global_colors_info=\u00bb{%22gcid-79008fab-ccde-4aaf-8238-1144e270bf33%22:%91%22border_color_all%22%93}\u00bb][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/webinar_FIELD.m4v\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_video][\/et_pb_column][et_pb_column type=\u00bb1_2″ _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.7em\u00bb header_5_text_color=\u00bb#000000″ header_6_text_color=\u00bbgcid-secondary-color\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb]<\/p>\n

Webinar del Estudio FIELD<\/span><\/h5>\n

2013<\/span><\/p>\n

Pr. Michel Hermans <\/span><\/h6>\n

El seminario web sobre el estudio FIELD analiza sus objetivos y conclusiones en relaci\u00f3n con el riesgo vascular residual. Destaca la importancia del estudio para definir futuras estrategias vasculares y su inter\u00e9s por comprender los factores subyacentes que contribuyen al riesgo residual. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a1Bienvenido\/a a la secci\u00f3n de Webinars de la Fundaci\u00f3n R3i! Aqu\u00ed ofrecemos una plataforma para el intercambio de conocimientos y el debate sobre temas clave relacionados con la salud vascular y el riesgo residual. Nuestros webinars cuentan con la participaci\u00f3n de reconocidos expertos de todo el mundo, que comparten sus conocimientos, investigaciones y estrategias innovadoras […]<\/p>\n","protected":false},"author":258497325,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wpcom_ai_launchpad_about_page":false,"_wpcom_ai_launchpad_gallery_page":false,"_wpcom_ai_launchpad_contact_page":false,"_wpcom_ai_launchpad_events_page":false,"_wpcom_ai_launchpad_video_page":false,"_wpcom_ai_launchpad_portfolio_piece":false,"footnotes":""},"class_list":["post-253114","page","type-page","status-publish","hentry"],"yoast_head":"\nWebinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual<\/title>\n<meta name=\"description\" content=\"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/es\/seminarios-web\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Webinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual\" \/>\n<meta property=\"og:description\" content=\"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/es\/seminarios-web\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T13:03:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/seminarios-web\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/seminarios-web\\\/\",\"name\":\"Webinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\"},\"datePublished\":\"2024-12-07T13:53:28+00:00\",\"dateModified\":\"2026-06-23T13:03:05+00:00\",\"description\":\"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/seminarios-web\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/es\\\/seminarios-web\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/seminarios-web\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seminarios web\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"publisher\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\",\"name\":\"R3I\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"width\":1601,\"height\":834,\"caption\":\"R3I\"},\"image\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Webinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual","description":"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/es\/seminarios-web\/","og_locale":"es_ES","og_type":"article","og_title":"Webinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual","og_description":"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.","og_url":"https:\/\/r3i.org\/es\/seminarios-web\/","og_site_name":"R3I","article_modified_time":"2026-06-23T13:03:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"9 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/es\/seminarios-web\/","url":"https:\/\/r3i.org\/es\/seminarios-web\/","name":"Webinars de expertos de R3i: conocimientos sobre salud vascular y riesgo residual","isPartOf":{"@id":"https:\/\/r3i.org\/es\/#website"},"datePublished":"2024-12-07T13:53:28+00:00","dateModified":"2026-06-23T13:03:05+00:00","description":"Accede a los seminarios web de R3i sobre la ulceraci\u00f3n del pie diab\u00e9tico, el manejo de la retinopat\u00eda con agonistas de PPAR\u03b1 y ensayos cl\u00ednicos emblem\u00e1ticos como ACCORD y FIELD. Aprende de expertos internacionales sobre el riesgo residual.","breadcrumb":{"@id":"https:\/\/r3i.org\/es\/seminarios-web\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/es\/seminarios-web\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/es\/seminarios-web\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/es\/"},{"@type":"ListItem","position":2,"name":"Seminarios web"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/es\/#website","url":"https:\/\/r3i.org\/es\/","name":"R3I","description":"Residual Risk Reduction Initiative","publisher":{"@id":"https:\/\/r3i.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/r3i.org\/es\/#organization","name":"R3I","url":"https:\/\/r3i.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","contentUrl":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","width":1601,"height":834,"caption":"R3I"},"image":{"@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/"}}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-13Qu","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/users\/258497325"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/comments?post=253114"}],"version-history":[{"count":14,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253114\/revisions"}],"predecessor-version":[{"id":257921,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253114\/revisions\/257921"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/media?parent=253114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}